C. F. Pollera

发表

Prognostic factors influencing cisplatin‐induced emesis. Definition and validation of a predictive logistic model

D. Giannarelli, C. F. Pollera, 1989, Cancer.

Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study.

F. Cognetti, A. Lombardi, G. Atlante, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized open cross-over trial between metoclopramide (MCP) and dexamethazone (DXM) for the prevention of cisplatin-induced nausea and vomiting.

F. Cognetti, P. Carlini, E. Conti, 1984, European journal of cancer & clinical oncology.

A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin

P. Carlini, M. Nardi, P. Marolla, 2004, Cancer Chemotherapy and Pharmacology.

Effective Control of CMF‐Related Emesis with High‐Dose Dexamethasone: Results of a Double‐Blind Crossover Trial with Metoclopramide and Placebo

D. Giannarelli, M. Nardi, E. Terzoli, 1989, American journal of clinical oncology.

Adoptive Immunotherapy of Advanced Cancer with LAK Cells and Different Dosages of Interleukin-2:Analysis of Lymphocyte Subpopulations

C. Peschle, G. Mariani, U. Testa, 1990 .

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum

G. Luporini, C. Gridelli, V. Lorusso, 1998 .

Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long-term effects

Franco Ameglio, M. Nardi, P. Marolla, 2004, Cancer Chemotherapy and Pharmacology.

Changes in serum iron levels following very high-dose cisplatin

M. R. Abbolito, Franco Ameglio, S. Reina, 2004, Cancer Chemotherapy and Pharmacology.

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer.

G. Luporini, C. Gridelli, V. Lorusso, 1998, European journal of cancer.

A feasibility study of gefitinib in association with capecitabine (CAP) and oxaliplatin (OXA) as first-line treatment in patients with advanced colorectal cancer (ACRC)

F. Costanzo, A. Gabriele, F. Cognetti, 2004 .

A feasibility study of gefitinib in association with capecitabine (CAP) and oxaliplatin (OXA) as first-line treatment in patients with advanced colorectal cancer (ACRC).

F. di Costanzo, A. Gabriele, F. Cognetti, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial

G. Muto, M. Gallucci, F. Cognetti, 2008 .

Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels

A. Ceribelli, C. Oliva, M. Crecco, 2004, Investigational New Drugs.

Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.

G. Muto, M. Gallucci, F. Cognetti, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Improved control of cisplatin-induced emesis with a metoclopramide-dexamethasone combination

F. Cognetti, P. Carlini, E. Ruggeri, 2004, Cancer Chemotherapy and Pharmacology.

More is better but ... how is best: are milligrams over hours better than grams over minutes? The case of gemcitabine.

C. F. Pollera, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High dose-intense chemotherapy alone or in combination with interleukin-2 for small cell lung cancer: a pilot study.

C. Peschle, U. Testa, D. Giannarelli, 1994, Cancer investigation.

SUDDEN DEATH AFTER ACUTE DYSTONIC REACTION TO HIGH-DOSE METOCLOPRAMIDE

F. Cognetti, M. Nardi, C. F. Pollera, 1984, The Lancet.

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study.

A. Ceribelli, M. Crecco, F. Calabresi, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Cisplatin-induced hepatic toxicity.

Franco Ameglio, G. Vitelli, M. Nardi, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study

F. Cognetti, L. Moscetti, P. Carlini, 2005, Cancer Chemotherapy and Pharmacology.

G. Muto, M. Gallucci, F. Cognetti, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A combination of ifosfamide and mitoxantrone as salvage therapy in patients with advanced ovarian cancer

G. Atlante, F. Calabresi, M. Nardi, 1996, Cancer Chemotherapy and Pharmacology.

Alizapride alone or alizapride-dexamethasone compared with metoclopramide-dexamethasone in patients at high risk of acute emesis after cisplatin. A randomized cross-over study.

F. Calabresi, M. Nardi, P. Marolla, 1991, Acta oncologica.

Nephroblastoma in the adult.

F. Cognetti, S. De Marco, C. F. Pollera, 1999, Medical and pediatric oncology.

Impact of gefitinib (‘Iressa’) treatment on the quality of life of patients with advanced non-small-cell lung cancer

A. Ceribelli, M. Milella, F. Cognetti, 2005, Journal of Cancer Research and Clinical Oncology.

Dose and schedule effects of cisplatin on the related acute iron changes.

P. Carlini, Franco Ameglio, M. Nardi, 1990, Oncology.

Gemcitabine: safety profile unaffected by starting dose.

C. Martín, C. F. Pollera, 1996, International journal of clinical pharmacology research.

Weekly gemcitabine in advanced or metastatic solid tumors

A. Ceribelli, F. Calabresi, C. F. Pollera, 2004, Investigational New Drugs.